Haemacure's Human Fibrin Sealant Demonstrates Effectiveness In Skin Graft Fixation Proof-of-Concept Study For Burn Injury Haemacure Corporation (TSX:HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, disclosed the positive results of a preclinical study conducted on the use of its proprietary lead product candidate, the human fibrin sealant Hemaseel(R)HMN, in skin graft fixation for burn victims.
Source: www.medicalnewstoday.com
# posted by Network @ 5:00 AM
